tiprankstipranks
Trending News
More News >

Isofol Medical Initiates Clinical Study for Arfolitixorin in Colorectal Cancer

Story Highlights

The latest update is out from Isofol Medical AB ( (SE:ISOFOL) ).

Isofol Medical AB has commenced a clinical phase Ib/II study of its drug candidate arfolitixorin, targeting metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to evaluate the benefit/risk profile and efficacy of arfolitixorin in a new dosing regimen. This milestone marks a significant step in Isofol’s plan to bring arfolitixorin closer to market, potentially offering improved treatment options for patients with advanced cancers.

More about Isofol Medical AB

Isofol Medical AB is a research-based biotechnology company focused on improving the prognosis for patients with severe forms of cancer. The company is developing arfolitixorin, a drug candidate aimed at enhancing the efficacy of first-line standard treatments for several solid tumors, with a current focus on colorectal cancer. Isofol Medical AB is listed on Nasdaq Stockholm.

YTD Price Performance: -15.76%

Technical Sentiment Signal: Buy

Current Market Cap: €27.86M

Learn more about ISOFOL stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App